SCHEMBL23218844

SCHEMBL23218844

OCCc1cc(Br)c2occc2c1F

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21437650 0.87 HTR2A (0.33) HTR2C
SCHEMBL23219171 0.82 HTR2A (0.33) HTR2C
SCHEMBL23218438 0.77 PTPN1 (0.31)
SCHEMBL24199941 0.76 KCNA2 (0.30)
SCHEMBL4992632 0.74 GYS1 (0.30) HTR2C
SCHEMBL26475950 0.73 PTPN1 (0.34)
SCHEMBL23218572 0.71 NPC1 (0.32) HTR2C
SCHEMBL6305380 0.71 HTR2A (0.32) HTR2C
SCHEMBL21438255 0.71 HTR2A (0.33) HTR2C
SCHEMBL16855179 0.70 DRD2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed